TCTR20190701001招募中2 期
Phase II, Multi-Center, Open-Label, Single-Arm Study Evaluating the Efficacy and Safety of Mycophenolate Mofetil in Patients with High-Grade Locally Advanced or Metastatic Osteosarcoma (ESMMO)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. High-grade locally advanced or metastatic osteosarcoma;
- •2. Measurable disease;
- •3. Evidence of disease progression after treatment with standard chemotherapy regimen or evidence of patient refusal for any further treatment with standard chemotherapy regimens;
- •4. ECOG performance status of <=2;
- •5. Age >=13 years;
- •6. Adequate organ function; and
- •7. Evidence of a personally signed and dated informed consent (or assent, when applicable) document.
排除标准
- •1. History of another malignancy within 5 years;
- •2. Current treatment with another investigational agent and/or systemic anticancer therapy;
- •3. Surgery and/or radiotherapy for curative intent;
- •4. History of allergic reactions attributed to mycophenolate mofetil, mycophenolic acid, or any ingredients of the drugs;
- •5. History of severe or uncontrolled medical conditions or laboratory abnormality;
- •6. Impaired renal function;
- •7. Known or suspected pregnancy or breastfeeding;
- •8. Any other conditions in which mycophenolate mofetil is contradicted;
- •9. Unable to swallow oral medications;
- •10. Major surgery; or
- •11. Significantly altered mental status.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Participants with Advanced Prostate CancerAdvanced prostate cancerMedDRA version: 20.0Level: PTClassification code: 10060862Term: Prostate cancer Class: 100000004864CTIS2023-509255-14-01Antev Limited44
进行中（未招募）
不适用
An Open-Label, Single-Arm, Multi-Center, Phase II/III study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in second salvageAcute Myeloid Leukemia (AML)EUCTR2005-001721-29-DESGX Pharmaceuticals, Inc.211
进行中（未招募）
1 期
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Women Whose Breast Cancer Expresses the Androgen Receptor but Does Not Express Estrogen or Progesterone Receptors, and is Not Amplified for the Epidermal Growth Factor Receptor, HER2MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast CancerEUCTR2013-000698-57-ITMedivation, Inc.80
进行中（未招募）
不适用
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Women Whose Breast Cancer Expresses the Androgen Receptor but Does Not Express Estrogen or Progesterone Receptors, and is Not Amplified for the Epidermal Growth Factor Receptor, HER2MedDRA version: 16.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast CancerEUCTR2013-000698-57-ESMedivation, Inc.80
进行中（未招募）
1 期
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Women Whose Breast Cancer Expresses the Androgen Receptor but Does Not Express Estrogen or Progesterone Receptors, and is Not Amplified for the Epidermal Growth Factor Receptor, HER2Breast CancerEUCTR2013-000698-57-GBMedivation, Inc.118